Find Gentamicin Sulfate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

USP

0

JP

FDF DossiersDRUG PRODUCT COMPOSITIONS

59RELATED EXCIPIENT COMPANIES

95EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

GLOBAL SALES INFORMATION

Annual Reports

NA

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Garamycin solution, Gentimicin sulfate solution, Gentamicin sulfate, 500x solution, Akos015895526, G0383
Molecular Formula
C21H45N5O11S
Molecular Weight
575.7  g/mol
InChI Key
NWQISSNHRDDWRM-UHFFFAOYSA-N

Gentamicin Sulfate
1 2D Structure

Gentamicin Sulfate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid
2.1.2 InChI
InChI=1S/C21H43N5O7.H2O4S/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20;1-5(2,3)4/h9-20,25-29H,5-8,22-24H2,1-4H3;(H2,1,2,3,4)
2.1.3 InChI Key
NWQISSNHRDDWRM-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC.OS(=O)(=O)O
2.2 Synonyms
2.2.1 Depositor-Supplied Synonyms

1. Garamycin Solution

2. Gentimicin Sulfate Solution

3. Gentamicin Sulfate, 500x Solution

4. Akos015895526

5. G0383

2.3 Create Date
2009-08-08
3 Chemical and Physical Properties
Molecular Weight 575.7 g/mol
Molecular Formula C21H45N5O11S
Hydrogen Bond Donor Count10
Hydrogen Bond Acceptor Count16
Rotatable Bond Count7
Exact Mass575.28362844 g/mol
Monoisotopic Mass575.28362844 g/mol
Topological Polar Surface Area283 Ų
Heavy Atom Count38
Formal Charge0
Complexity717
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count13
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameGenoptic
PubMed HealthGentamicin
Drug ClassesAntibacterial, Antibiotic
Active IngredientGentamicin sulfate
Dosage FormSolution/drops
RouteOphthalmic
Strengtheq 0.3% base
Market StatusPrescription
CompanyAllergan

2 of 2  
Drug NameGenoptic
PubMed HealthGentamicin
Drug ClassesAntibacterial, Antibiotic
Active IngredientGentamicin sulfate
Dosage FormSolution/drops
RouteOphthalmic
Strengtheq 0.3% base
Market StatusPrescription
CompanyAllergan

API SUPPLIERS

read-more
read-more

01

Livzon Group Fuzhou Fuxing Pharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

Livzon Group Fuzhou Fuxing Pharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF arrow-down Others AUDIT arrow-down
blank

02

Lek Pharmaceuticals

Slovenia

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

Lek Pharmaceuticals

Slovenia

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF arrow-down EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

03

ACS DOBFAR SPA

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

ACS DOBFAR SPA

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

04

Fujian Fukang Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

Fujian Fukang Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF arrow-down EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

05

SHANGHAI ASIA PHARMACEUTICAL CO LT...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

SHANGHAI ASIA PHARMACEUTICAL CO LT...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

Fermic

Mexico

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

Fermic

Mexico

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

07

Meiji Seika Pharma

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

Meiji Seika Pharma

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Kaifeng Pharmaceutical Group Co., ...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

Kaifeng Pharmaceutical Group Co., ...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

Fermic Sa De Cv

Mexico

USDMF

arrow
PEGS Boston Summit
Not Confirmed

01

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 14753

Submission : 1998-09-01

Status : Inactive

Type : II

blank

02

PEGS Boston Summit
Not Confirmed

02

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2013-09-21

Pay. Date : 2013-09-11

DMF Number : 12048

Submission : 1996-06-30

Status : Active

Type : II

blank

03

Lek Pharmaceuticals Dd

Slovenia

USDMF

arrow
PEGS Boston Summit
Not Confirmed

03

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 13704

Submission : 1998-09-01

Status : Active

Type : II

blank

04

PEGS Boston Summit
Not Confirmed

04

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 13658

Submission : 1998-09-01

Status : Inactive

Type : II

blank

05

PEGS Boston Summit
Not Confirmed

05

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 13630

Submission : 1998-09-01

Status : Inactive

Type : II

blank

06

PEGS Boston Summit
Not Confirmed

06

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 13637

Submission : 1998-09-01

Status : Inactive

Type : II

blank

07

Yantai No 2 Pharmaceutical Factory

Country

USDMF

arrow
PEGS Boston Summit
Not Confirmed

07

Yantai No 2 Pharmaceutical Factory

Country
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 14866

Submission : 2000-05-04

Status : Inactive

Type : II

blank

08

Ansa Antibiotik Ve Ilac Hammadderi S...

Country

USDMF

arrow
PEGS Boston Summit
Not Confirmed

08

Ansa Antibiotik Ve Ilac Hammadderi S...

Country
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 13671

Submission : 1998-09-01

Status : Inactive

Type : II

blank

09

Pharmachim Economic Corp

Country

USDMF

arrow
PEGS Boston Summit
Not Confirmed

09

Pharmachim Economic Corp

Country
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 13625

Submission : 1998-09-01

Status : Inactive

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

GENTAMICIN SULFATE

NDC Package Code : 52946-0605

Start Marketing Date : 2010-04-19

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

GENTAMICIN SULFATE

NDC Package Code : 69988-0065

Start Marketing Date : 2025-02-28

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/1)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

GENTAMICIN SULFATE

NDC Package Code : 67630-0003

Start Marketing Date : 2011-03-09

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

GENTAMICIN SULFATE

NDC Package Code : 60592-301

Start Marketing Date : 2019-11-29

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

GENTAMICIN

NDC Package Code : 48866-8256

Start Marketing Date : 2013-07-12

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (10kg/10kg)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

GENTAMICIN SULFATE

NDC Package Code : 62991-1072

Start Marketing Date : 2011-03-31

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

GENTAMICIN SULFATE

NDC Package Code : 42513-0008

Start Marketing Date : 2014-09-22

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

Medisca Inc.

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Medisca Inc.

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

GENTAMICIN SULFATE

NDC Package Code : 38779-0632

Start Marketing Date : 2014-06-16

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank

09

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

GENTAMICIN SULFATE

NDC Package Code : 51927-0252

Start Marketing Date : 2020-08-25

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more
  • Development Update

Details:

Gentamicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Appendicitis.


Lead Product(s): Gentamicin Sulfate,Clindamycin Hydrochloride

Therapeutic Area: Gastroenterology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: ZonMw

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 21, 2025

blank

01

Spaarne Gasthuis

Country
arrow
PEGS Boston Summit
Not Confirmed

Spaarne Gasthuis

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Gentamicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Appendicitis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 21, 2025

blank
  • Development Update

Details:

Vancomycin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Pressure Ulcer.


Lead Product(s): Vancomycin Hydrochloride,Gentamicin Sulfate,Calcium Sulfate

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Antibiotic

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 05, 2025

blank

02

Biocomposites

Country
arrow
PEGS Boston Summit
Not Confirmed

Biocomposites

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Vancomycin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Pressure Ulcer.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Inapplicable

February 05, 2025

blank
  • Development Update

Details:

Vancomycin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pressure Ulcer.


Lead Product(s): Vancomycin Hydrochloride,Gentamicin Sulfate,Calcium Sulfate

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Antibiotic

Sponsor: MCRA

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 28, 2024

blank

03

Biocomposites

Country
arrow
PEGS Boston Summit
Not Confirmed

Biocomposites

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Vancomycin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pressure Ulcer.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Inapplicable

February 28, 2024

blank

Details:

BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of atopic dermatitis. Bacterial biofilms are specialized communities consisting of bacteria adhered to a surface and to other bacteria.


Lead Product(s): Gentamicin Sulfate,Inapplicable

Therapeutic Area: Dermatology Brand Name: BioLexa

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 06, 2023

blank

04

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of atopic dermatitis. Bacterial biofilms are specialized communities consisting of bacteria adhered to a surface and to other bacteria.

Product Name : BioLexa

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 06, 2023

blank
  • Development Update

Details:

Ampicillin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Premature Birth.


Lead Product(s): Ampicillin,Gentamicin Sulfate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Antibiotic

Sponsor: The University of Pittsburgh School of Medicine | Morgan Stanley Children’s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 04, 2023

blank

05

Sharp HealthCare

Country
arrow
PEGS Boston Summit
Not Confirmed

Sharp HealthCare

Country
arrow
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Ampicillin,Gentamicin Sulfate

Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : The University of Pittsburgh School of Medicine | Morgan Stanley Children’s Hospital | University of Louisville | Sharp Mary Birch Hospital for Women & Newborns | Children's Hospital of Philadelphia | Jefferson Medical College of Thomas Jefferson Universi

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Ampicillin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Premature Birth.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Inapplicable

August 04, 2023

blank
  • Development Update

Details:

Ceftriaxone is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Cholangitis.


Lead Product(s): Ceftriaxone,Gentamicin Sulfate,Cefuroxime Axetil,Ciprofloxacin

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Antibiotic

Sponsor: ZonMw

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 02, 2023

blank

06

Academisch Medisch Centrum - Universiteit van Amsterdam

Country
arrow
PEGS Boston Summit
Not Confirmed

Academisch Medisch Centrum - Universiteit van Amsterdam

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Ceftriaxone is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Cholangitis.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Inapplicable

March 02, 2023

blank
  • Development Update

Details:

Gentamicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Tract Infections.


Lead Product(s): Gentamicin Sulfate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Northeast Ohio Medical University

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 27, 2023

blank

07

Mercy Health

Country
arrow
PEGS Boston Summit
Not Confirmed

Mercy Health

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Gentamicin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Tract Infections.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 27, 2023

blank

Details:

BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. Bacterial biofilms are specialized communities consisting of bacteria adhered to a surface and to other bacteria.


Lead Product(s): Gentamicin Sulfate,Pentetic Acid

Therapeutic Area: Dermatology Brand Name: BioLexa

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: H.C. Wainwright & Co

Deal Size: $10.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement January 03, 2023

blank

08

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. Bacterial biofilms are specialized communities consisting of bacteria adhered to a surface an...

Product Name : BioLexa

Product Type : Miscellaneous

Upfront Cash : Undisclosed

January 03, 2023

blank

Details:

BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. The BioLexa formulation is optimized to prevent Staphylococcal biofilm formation.


Lead Product(s): Gentamicin Sulfate,Pentetic Acid

Therapeutic Area: Dermatology Brand Name: BioLexa

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: H.C. Wainwright & Co

Deal Size: $10.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement December 29, 2022

blank

09

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. The BioLexa formulation is optimized to prevent Staphylococcal biofilm formation.

Product Name : BioLexa

Product Type : Miscellaneous

Upfront Cash : Undisclosed

December 29, 2022

blank
  • Development Update

Details:

Vancomycin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteomyelitis.


Lead Product(s): Vancomycin Hydrochloride,Gentamicin Sulfate,Calcium Sulfate

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Antibiotic

Sponsor: MCRA

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 14, 2022

blank

10

Biocomposites

Country
arrow
PEGS Boston Summit
Not Confirmed

Biocomposites

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Vancomycin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteomyelitis.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Inapplicable

September 14, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Gentamicin

Brand Name : Gentamicin

Dosage Form :

Dosage Strength : Cream Derm 30 G 0,1%  

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

Sanofi

02

Gentamicin; Betamethasone

Brand Name : Gentamicin Betamethasone

Dosage Form :

Dosage Strength : Cream Derm 30 G 0.1% + 0.1%  

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

Sanofi

03

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

Brand Name : PRED-G

Dosage Form : SUSPENSION/DROPS;OPHTHALMIC

Dosage Strength : EQ 0.3% BASE;1%

Packaging :

Approval Date : 1988-06-10

Application Number : 50586

Regulatory Info : DISCN

Registration Country : USA

Abbvie CB

04

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

Brand Name : PRED-G

Dosage Form : OINTMENT;OPHTHALMIC

Dosage Strength : EQ 0.3% BASE;0.6%

Packaging :

Approval Date : 1989-12-01

Application Number : 50612

Regulatory Info : DISCN

Registration Country : USA

Abbvie CB

05

GENTAMICIN SULFATE

Brand Name : GENOPTIC

Dosage Form : SOLUTION/DROPS;OPHTHALMIC

Dosage Strength : EQ 0.3% BASE

Packaging :

Approval Date : 1984-10-10

Application Number : 62452

Regulatory Info : DISCN

Registration Country : USA

Abbvie CB

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOctavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Clotrimazole; Beclomethasone Dipropionate; Gentamicin Sulfate

Brand Name : Clotrimazole; Beclomethasone Dipropionate; Gentamicin Sulfate

Dosage Form : Cream

Dosage Strength : 1%; 0.025%; 0.1%

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Octavius Pharma

07

Bayer AG

Germany
PEGS Boston Summit
Not Confirmed
arrow

Bayer AG

Germany
arrow
PEGS Boston Summit
Not Confirmed

GENTAMICIN SULFATE

Brand Name : GARAMYCIN

Dosage Form : SOLUTION/DROPS;OPHTHALMIC

Dosage Strength : EQ 0.3% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Packaging :

Approval Date : 1982-01-01

Application Number : 50039

Regulatory Info : DISCN

Registration Country : USA

blank

08

Bayer AG

Germany
PEGS Boston Summit
Not Confirmed
arrow

Bayer AG

Germany
arrow
PEGS Boston Summit
Not Confirmed

GENTAMICIN SULFATE

Brand Name : GARAMYCIN

Dosage Form : OINTMENT;OPHTHALMIC

Dosage Strength : EQ 0.3% BASE

Packaging :

Approval Date : 1982-01-01

Application Number : 50425

Regulatory Info : DISCN

Registration Country : USA

blank

09

Bayer AG

Germany
PEGS Boston Summit
Not Confirmed
arrow

Bayer AG

Germany
arrow
PEGS Boston Summit
Not Confirmed

GENTAMICIN SULFATE

Brand Name : GARAMYCIN

Dosage Form : INJECTABLE;INTRATHECAL

Dosage Strength : EQ 2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Packaging :

Approval Date : 1982-01-01

Application Number : 50505

Regulatory Info : DISCN

Registration Country : USA

blank

10

Bayer AG

Germany
PEGS Boston Summit
Not Confirmed
arrow

Bayer AG

Germany
arrow
PEGS Boston Summit
Not Confirmed

GENTAMICIN SULFATE

Brand Name : GARAMYCIN

Dosage Form : CREAM;TOPICAL

Dosage Strength : EQ 0.1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Packaging :

Approval Date : 1982-01-01

Application Number : 60462

Regulatory Info : DISCN

Registration Country : USA

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - SUSPENSION/DROPS;OPHTHALMIC - EQ 0.3...DOSAGE - SUSPENSION/DROPS;OPHTHALMIC - EQ 0.3% BASE;1%

USFDA APPLICATION NUMBER - 50586

read-more

DOSAGE - OINTMENT;OPHTHALMIC - EQ 0.3% BASE;0...DOSAGE - OINTMENT;OPHTHALMIC - EQ 0.3% BASE;0.6%

USFDA APPLICATION NUMBER - 50612

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Parenteral

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Topical

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Solubilizers

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Taste Masking

read-more
read-more

Controlled & Modified Release

read-more
read-more

Emulsifying Agents

read-more
read-more

Lubricants & Glidants

read-more
read-more

Direct Compression

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

API Stability Enhancers

read-more
read-more

Granulation

read-more
read-more

Soft Gelatin

read-more
read-more

Co-Processed Excipients

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF DOSSIERS

read-more
read-more
Delivery of antibacterial agents for systemic use for the needs of "Dr. Stoycho Hristov" Hospital EOOD, SEVLIEVO. The deadline for the submission of the bid is 13-Nov-2020. 1. Amoxicillin (1000 mg) Tablets 2. Amoxicillin (1000 mg) + Clavulanic Acid (200 mg) 3. Ampicillin Sodium (1 g) + Sulbactam Sodium (0.5 g) Powder Injections 4. Piperacillin (4 g) + Tazobactam (500 mg) Powder Injections / Infusions 5. Cefotaxime (1 g) Powder Injections 6. Ceftazidime (1 g) Powder Injections 7. Ceftriaxone (1 g) Powder Injections 8. Ceftriaxone (2 g) Powder Injections 9. Cefoperazone Sodium (2 g) Powder Injections 10. Cefoperazone (1 g) + Sulbactam (1 g) Powder Injections 11. Cefepime (1 g) Powder Injections 12. Meropenem (1 g) Powder Injections / Infusions 13. Clarithromycin (500 mg) Powder for Infusions 14. Azithromycin (500 mg) Powder for Infusions 15. Azithromycin (200 mg /5 ml in 20 ml) Oral Suspensions 16. Azithromycin (500 mg) 17. Clindamycin Phosphate (150 mg/ ml in 4 ml) 18. Gentamicin (40 mg/ml in 2 ml) Injections 19. Amikacin (125 mg/ml in 2 ml) Injections/ Infusions 20. Amikacin (250 mg/ ml in 2 ml) Injections/ Infusions 21. Amikacin (5 mg/ ml in 100 ml) Injections / Infusions 22. Ciprofloxacin (100 mg in 10 ml) Infusions 23. Ciprofloxacin (200 mg/ 100 ml in 100 ml) Infusions 24. Ciprofloxacin (400 mg/ 200 ml in 200 ml) Infusions 25. Ciprofloxacin (500 mg) 26. Levofloxacin (5 mg/ ml in 100 ml) Injections 27. Levofloxacin (500 mg) 28. Vancomycin (1 g) Powder Infusions 29. Metronidazole (500 mg in 100 ml) Infusions 30. Ampicillin (1 g)
10 Nov 2020

Reply

10 Nov 2020

Reply text-arrow

Reply Comment (9)

10 Nov 2020

click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ANALYTICAL

Upload your methods for free, ask us

ABOUT THIS PAGE

Looking for / Gentamicin Sulfate API manufacturers, exporters & distributors?

Gentamicin Sulfate manufacturers, exporters & distributors 1

12

PharmaCompass offers a list of Gentamicin Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Gentamicin Sulfate manufacturer or Gentamicin Sulfate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gentamicin Sulfate manufacturer or Gentamicin Sulfate supplier.

API | Excipient name

Gentamicin Sulfate

Synonyms

Garamycin solution, Gentimicin sulfate solution, Gentamicin sulfate, 500x solution, Akos015895526, G0383

Gentamicin Manufacturers

A Gentamicin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gentamicin, including repackagers and relabelers. The FDA regulates Gentamicin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gentamicin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Gentamicin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Gentamicin Suppliers

A Gentamicin supplier is an individual or a company that provides Gentamicin active pharmaceutical ingredient (API) or Gentamicin finished formulations upon request. The Gentamicin suppliers may include Gentamicin API manufacturers, exporters, distributors and traders.

click here to find a list of Gentamicin suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Gentamicin USDMF

A Gentamicin DMF (Drug Master File) is a document detailing the whole manufacturing process of Gentamicin active pharmaceutical ingredient (API) in detail. Different forms of Gentamicin DMFs exist exist since differing nations have different regulations, such as Gentamicin USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Gentamicin DMF submitted to regulatory agencies in the US is known as a USDMF. Gentamicin USDMF includes data on Gentamicin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Gentamicin USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Gentamicin suppliers with USDMF on PharmaCompass.

Gentamicin JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Gentamicin Drug Master File in Japan (Gentamicin JDMF) empowers Gentamicin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Gentamicin JDMF during the approval evaluation for pharmaceutical products. At the time of Gentamicin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Gentamicin suppliers with JDMF on PharmaCompass.

Gentamicin KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Gentamicin Drug Master File in Korea (Gentamicin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Gentamicin. The MFDS reviews the Gentamicin KDMF as part of the drug registration process and uses the information provided in the Gentamicin KDMF to evaluate the safety and efficacy of the drug.

After submitting a Gentamicin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Gentamicin API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Gentamicin suppliers with KDMF on PharmaCompass.

Gentamicin CEP

A Gentamicin CEP of the European Pharmacopoeia monograph is often referred to as a Gentamicin Certificate of Suitability (COS). The purpose of a Gentamicin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Gentamicin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Gentamicin to their clients by showing that a Gentamicin CEP has been issued for it. The manufacturer submits a Gentamicin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Gentamicin CEP holder for the record. Additionally, the data presented in the Gentamicin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Gentamicin DMF.

A Gentamicin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Gentamicin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Gentamicin suppliers with CEP (COS) on PharmaCompass.

Gentamicin NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Gentamicin as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Gentamicin API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Gentamicin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Gentamicin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Gentamicin NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Gentamicin suppliers with NDC on PharmaCompass.

Gentamicin GMP

Gentamicin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Gentamicin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Gentamicin GMP manufacturer or Gentamicin GMP API supplier for your needs.

Gentamicin CoA

A Gentamicin CoA (Certificate of Analysis) is a formal document that attests to Gentamicin's compliance with Gentamicin specifications and serves as a tool for batch-level quality control.

Gentamicin CoA mostly includes findings from lab analyses of a specific batch. For each Gentamicin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Gentamicin may be tested according to a variety of international standards, such as European Pharmacopoeia (Gentamicin EP), Gentamicin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gentamicin USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty